03.12.2025

A study from Karolinska Institutet reports that a rapid point-of-care test may support screening for latent tuberculosis infection in settings with limited laboratory capacity. The analysis compares TB-Feron with the established QuantiFERON-TB Gold Plus test and highlights opportunities for faster diagnosis and improved access to preventive treatment.

The image shows a lab technician operating specialized diagnostic instruments

Automated laboratory equipment processes diagnostic samples used to assess rapid point-of-care tests for detecting latent tuberculosis infection.

Products and exhibitors related to this topic

Exhibitors and products related to this topic can be found in the database of MEDICA:

Why improved screening for latent TB is essential

Tuberculosis continues to cause severe illness globally. Individuals with latent TB carry bacteria without symptoms but may progress to active disease, increasing transmission risks. Early identification is therefore crucial to initiate preventive treatment and protect communities.

Currently, screening often relies on the QuantiFERON-TB Gold Plus assay, a multi-step laboratory method requiring specialized equipment and trained personnel. As processing takes one to two days, its use is limited in rural clinics and areas with constrained resources.

Comparing TB-Feron with the established laboratory test

Researchers from Karolinska Institutet and partners in Vietnam compared the performance of the TB-Feron point-of-care test with QuantiFERON-TB Gold Plus. TB-Feron delivers results in approximately 15 minutes and does not require advanced laboratory facilities.

Study design

The study enrolled 345 adults in Hanoi, divided into three groups:

individuals with confirmed tuberculosis,
household contacts of infectious TB cases,
people with no known exposure.

All participants were tested with both TB-Feron and QuantiFERON-TB Gold Plus.

Sensitivity and specificity outcomes

TB-Feron demonstrated a sensitivity of 88 percent, meaning most expected positive cases were correctly identified. QuantiFERON-TB Gold Plus reached 92 percent sensitivity.
However, the specificity of TB-Feron, the ability to rule out infection in healthy individuals, was 70 percent, compared with 96 percent for the established laboratory method.
Among household contacts, concordance between the two tests was high at 92 percent for positive samples.

Perspectives from the research team

Han Thi Nguyen states: “It is promising that TB-Feron works so well in an environment with a high disease burden. The test is patient-friendly and easy to use, with rapid same-day results, making it useful in primary care.”
To assess reproducibility, results were compared across two groups of laboratory professionals. No systematic differences were observed, suggesting stable performance.
Lina Davies Forsman adds: “This test can help more people with latent tuberculosis to be detected and receive preventive treatment, especially in rural areas in countries with limited resources.”

MEDICA-tradefair.com; Source: Karolinska Institutet

More about the Karolinska Institutet at: ki.se/en